Trastuzumab is a recombinant humanized monoclonal antibody that is used in the treatment of cancer.
This product comes in a liquid form with a protein content of >15 mg/mL.
This product comes in a liquid form with a protein content of >15 mg/mL.
| Mechanism of Action | HER2 is a receptor tyrosine kinase and epidermal growth factor which overexpresses in breast cancer cells causing over-proliferation. Trastuzumab targets the extracellular domain IV of HER2, keeping it from dimerizing and activating. |
| Molecular Formula | C6470H10012N1726O2013S42 |
| References | Vu, T., & Claret, F. X. (2012). Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer. Frontiers in Oncology, 2, 62. http://doi.org/10.3389/fonc.2012.00062 |